Lite Strategy (LITS) Accounts Payables (2011 - 2026)
Lite Strategy (LITS) posted quarterly Accounts Payables of $253000.0 for Q1 2026, up 42.94% year-over-year from $177000.0 in Q1 2025, and down 22.63% quarter-over-quarter from $327000.0 in Q4 2025.
Lite Strategy (LITS) Accounts Payables (2011 - 2026) Analysis & Trends
Lite Strategy's Accounts Payables history runs 16 years deep, the most recent figure standing at $253000.0 for Q1 2026.
- In Q1 2026, Accounts Payables rose 42.94% year-over-year to $253000.0; the TTM figure through Mar 2026 stood at $253000.0 (up 42.94% YoY), while the FY2025 annual figure was $176000.0, down 94.44% from the prior year.
- Accounts Payables for Q1 2026 stood at $253000.0, down from $327000.0 in the prior quarter.
- The five-year high for Accounts Payables was $8.4 million in Q3 2022, with the low at $176000.0 in Q2 2025.
- The 5-year median for Accounts Payables is $3.2 million (2024), against an average of $3.1 million.
- The sharpest annual moves came in 2022 and 2025: Accounts Payables jumped 48.21% in 2022, then tumbled 94.44% in 2025.
- Lite Strategy's Accounts Payables stood at $4.1 million in 2022, then plunged by 66.12% to $1.4 million in 2023, then slumped by 56.75% to $596000.0 in 2024, then tumbled by 45.13% to $327000.0 in 2025, then dropped by 22.63% to $253000.0 in 2026.
- Business Quant data shows LITS's Accounts Payables at $253000.0 in Q1 2026, $327000.0 in Q4 2025, and $503000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Lite Strategy | 35.71 Mn | 28.17 Mn | - | 253,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 253,000.00 |
| Dec 31, 2025 | 327,000.00 |
| Sep 30, 2025 | 503,000.00 |
| Jun 30, 2025 | 176,000.00 |
| Mar 31, 2025 | 177,000.00 |
| Dec 31, 2024 | 596,000.00 |
| Sep 30, 2024 | 976,000.00 |
| Jun 30, 2024 | 3.17 Mn |
| Mar 31, 2024 | 3.18 Mn |
| Dec 31, 2023 | 1.38 Mn |
| Sep 30, 2023 | 3.22 Mn |
| Jun 30, 2023 | 6.13 Mn |
| Mar 31, 2023 | 4.39 Mn |
| Dec 31, 2022 | 4.07 Mn |
| Sep 30, 2022 | 8.42 Mn |
| Jun 30, 2022 | 7.92 Mn |
| Mar 31, 2022 | 8.26 Mn |
| Dec 31, 2021 | 6.26 Mn |
| Sep 30, 2021 | 8.47 Mn |
| Jun 30, 2021 | 6.36 Mn |